Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Pfizer is voluntarily withdrawing its sickle cell disease (SCD) therapy Oxbryta from all world markets after finding an "imbalance" in deaths in its clinical trials programme. It's a blow to the SCD ...

Entering text into the input field will update the search result below Entering text into the input field will update the search result below ...

Novartis has said it is “disappointed” that the EMA’s Human Medicines Committee has recommended revoking the conditional EU approval for sickle cell disease (SCD) therapy Adakveo, and that it can no ...

Hypertrophic cardiomyopathy (HCM) is the most common hereditary cardiac condition and the leading cause of sudden cardiac death (SCD) in young adults. Given that SCD can be the first and most ...

Mar. 17, 2026 A new clinical study suggests that successful root canal treatment may benefit more than just dental health. Patients treated for infected teeth showed improved blood sugar control, ...